Investor Presentaiton
Investor presentation
First three months of 2017
Slide 4
Highlights
Sales development
-
First three months of 2017
Sales increased by 5% in Danish kroner and 3% in local currencies
•
●
North America Operations grew by 5% in Danish kroner and accounted for 34% share of growth in local currencies
International Operations grew by 4% in Danish kroner and accounted for 66% share of growth in local currencies
Region Europe grew by 4% in Danish kroner
Japan & Korea grew by 10% in Danish kroner
Region China grew by 6% in Danish kroner
TresibaⓇ grew 174% in Danish kroner and now represents 5% of total sales
Research and Development
EU approval of label update for TresibaⓇ based on data from SWITCH trials
Resubmission of new drug application for fast-acting insulin aspart in the US
Positive CHMP opinion for Refixia® (N9-GP) in the EU
Financials
Operating profit increased by 10% in Danish kroner and by 6% in local currencies
Diluted earnings per share increased by 9% to 4.06 DKK per share
2017 financial outlook:
• Reported sales growth is now expected to be 1-4% (now around 1% lower in local currencies)
•
Reported operating profit growth is now expected to be around 0-4% (now around 1% lower in local currencies)
CHMP: Committee for Medicinal Products for Human Use in Europe
changing
diabetes®
novo nordiskView entire presentation